Employees: 82
Size GI Innovation (358570.KS) is a South Korea Health Care company (Biotechnology) with a market value of $339M, the 444th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩7,030 on 18 Nov 2026.
Performance Over six months the shares fell 47.3%, against -24.7% for the median peer and -37.2% for the South Korea market (cap-weighted) — 4th lowest of 20 in its peer set.
Growth Revenue grew 1,526.8% over the last twelve months (peer median +4.2%); the operating margin is -918.1% (peer median -173.2%).
Valuation It trades at 78.5× enterprise value to sales against a peer median of 5.4× (5th most expensive of 16).
Capital Return on invested capital runs 65.7 points below its cost of capital (6.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩5.50B | ₩5.84B | ₩24.3M | ₩5.32B | ₩3.50B |
| Revenue growth | — | +23,943% | -100% | +52% | — |
| Gross profit | ₩3.48B | ₩2.85B | -₩3.08B | ₩1.99B | ₩343M |
| EBITDA | -₩48.5B | -₩38.7B | -₩45.5B | -₩52.3B | -₩67.2B |
| Net income | -₩44.6B | -₩35.1B | -₩58.8B | -₩55.5B | -₩79.8B |
| Free cash flow | -₩50.8B | -₩39.7B | -₩43.5B | -₩41.7B | -₩65.5B |
| Capital expenditure | ₩7.97B | ₩7.54B | ₩24.7M | ₩579M | ₩2.97B |
| Total debt | ₩1.75B | ₩5.03B | ₩12.0B | ₩3.72B | ₩4.27B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 358570.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.3% | -2.5% | 7th lowest of 20 |
| 6-month return | -47.3% | -24.7% | 4th lowest of 20 |
| Distance from 52-week high | -66.4% | -51.5% | 4th lowest of 20 |
| Revenue growth (TTM) | +1,526.8% | +4.2% | highest of 14 |
| Operating margin | -918.1% | -173.2% | 6th lowest of 16 |
| EV / Sales | 78.5× | 5.4× | 5th most expensive of 16 |
| ROIC minus cost of capital | -65.7 pp | -39.6 pp | 6th lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| GI Innovation 358570.KS | South Korea | $339M | -47% | +1,527% | -918% | 78.5× | n/a | n/a |
| Larimar Therapeutics LRMR | United States | $337M | -9% | n/a | n/a | n/a | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $341M | -19% | -63% | -1,388,360% | 13,911.5× | n/a | n/a |
| Medtide 3880.HK | Hong Kong | $331M | -17% | +14% | 36% | 2.4× | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $349M | n/a | n/a | n/a | n/a | n/a | n/a |
| Medy-Tox 086900.KS | South Korea | $350M | -36% | +3% | 10% | 2.2× | 4.7% | +11.9% |
| Laekna 2105.HK | Hong Kong | $326M | -53% | n/a | -57% | 4.7× | n/a | n/a |
| C4 Therapeutics CCCC | United States | $325M | -25% | +7% | -316% | 5.4× | n/a | n/a |
| CorMedix CRMD | United States | $358M | -43% | +92% | 39% | 0.4× | n/a | n/a |
| AP Biosciences 6945.TWO | Taiwan | $321M | -31% | n/a | n/a | n/a | n/a | n/a |
| IMPACT Therapeutics 7630.HK | Hong Kong | $319M | -79% | +395% | -173% | 9.5× | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $363M | -31% | n/a | n/a | n/a | n/a | n/a |
| ProKidney PROK | United States | $314M | -38% | +4% | -24,830% | 1,625.4× | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $368M | -49% | +179% | 21% | 5.2× | 0.6% | +725.2% |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $370M | -31% | 0% | -4% | 2.6× | n/a | n/a |
| Nautilus Biotechnolgy NAUT | United States | $310M | +2% | n/a | -15,106% | 588.9× | n/a | n/a |
| Cuorips 4894.T | Japan | $309M | -10% | -80% | -1,765% | 602.9× | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $378M | -15% | -4% | -1,617% | 27.4× | n/a | n/a |
| X4 Pharmaceuticals XFOR | United States | $304M | -21% | -50% | -474% | 11.4× | n/a | n/a |
| Viva Biotech 1873.HK | Hong Kong | $303M | -18% | +7% | 10% | 1.0× | 2.6% | +19.1% |
| Greenwich LifeSciences GLSI | United States | $302M | -25% | n/a | n/a | n/a | n/a | n/a |